US equities
|
NVDA
$240.09
▲+0.50%
SPCX
$173.81
▲+1.59%
MU
$1,062.93
▼-0.10%
MRVL
$282.01
▲+3.97%
AMD
$654.64
▲+3.62%
INTC
$114.09
▼-1.81%
SNDK
$1,669.84
▼-2.01%
AVGO
$377.59
▲+4.16%
NVDA
$240.09
▲+0.50%
SPCX
$173.81
▲+1.59%
MU
$1,062.93
▼-0.10%
MRVL
$282.01
▲+3.97%
AMD
$654.64
▲+3.62%
INTC
$114.09
▼-1.81%
SNDK
$1,669.84
▼-2.01%
AVGO
$377.59
▲+4.16%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Cordis
The Cordis SELUTION SLR SUSTANE™ PTA Drug Eluting Balloon achieves highest reported Primary Patency in US IDE Trial
Today 9:02 EDT
From
Cordis
Via
Business Wire
SELUTION SLR™ Drug-Eluting Balloon Approved by FDA for In-Stent Restenosis: First and Only Sirolimus Drug-Eluting Balloon in the US
September 21, 2026
From
Cordis
Via
Business Wire
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
April 28, 2026
From
Cordis
Via
Business Wire
Cordis to Present SELUTION SLR™ Drug-Eluting Balloon Clinical Data at CRT 2026
March 04, 2026
From
Cordis
Via
Business Wire